StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Rev $2.82 Million, bought HC & Aristotle launched;)

<< Previous

Bullboard Posts

Next >>

Comment by Jonnyboy85on Apr 03, 2021 4:43pm

91 Views

Post# 32934235

RE:RE:Rev $2.82 Million, bought HC & Aristotle launched;)

Jonnyboy85 wrote: @Relevant this is the excerpt from the Q4 press release, I highlighted in yellow where they pointed to covid rev that will fund the marketing Aristotle and AVRT etc. Also here is the link,

https://www.accesswire.com/638698/StageZero-Life-Sciences-Announces-Q4-2020-and-Year-End-Financial-Results-and-Operational-Update

Jonnyboy85 wrote: Scatter little roaches, scatter

Operational Update and Recent Highlights
The following milestones were achieved during the fourth quarter:

Received revenue of $2.82 million for the period.

Closed a prospectus offering of more than C$7M.

Hired additional staff and purchased equipment, test reagents, and consumable materials (for COVID-19 Tests and Aristotle®).

The following has been achieved in the first quarter of 2021:

Aristotle launched as part of the AVRT Program

Acquisition of Health Clinics Limited

Expanded testing in Canada via the Company's partnership with Ichor Blood Services.

Hired further staff and expanded testing capacity, both for COVID-19 and Aristotle®.

Participated in two investor focused conferences.

"Revenue from 2020 and 2021 supports the Company's efforts for commercialization and marketing of AVRT and Aristotle" said James Howard-Tripp, Chairman and CEO of StageZero. "We are pleased to have Health Clinics and Care Oncology as our partner, with the infrastructure in place, to support the uptake of these very innovative products"